Ingersoll Rand (IR) Q4 2025: Recurring Revenue Backlog Hits $1.1B, Bolstering Durable Growth Playbook
Ingersoll Rand’s disciplined M&A and recurring revenue engine are driving resilient performance and future visibility even as volume recovery remains muted. The company’s $1.1 billion recurring revenue backlog and robust bolt-on acquisition pipeline support a stable outlook, while tariff headwinds and measured capital deployment shape near-term margin dynamics. Management’s guidance signals a steady, no-recovery baseline for 2026, with incremental upside possible if short-cycle demand accelerates.
Summary
- Recurring Revenue Momentum: Contracted backlog and $450 million annual run-rate reinforce visibility and margin stability.
- M&A Discipline Persists: Bolt-on acquisitions expand capabilities with pre-synergy multiples averaging nine times, supporting above-market growth.
- Guidance Anchored in Caution: 2026 outlook assumes no market recovery, setting up for potential upside if industrial demand inflects.
Business Overview
Ingersoll Rand is a global provider of mission-critical flow creation and industrial technologies, operating through two primary segments: Industrial Technologies and Services (ITS), which delivers compressors, vacuum, and blowers, and Precision and Science Technologies (PST), focusing on specialized pumps, life sciences, and process solutions. The company generates revenue from equipment sales, aftermarket services, and an expanding base of recurring revenue contracts, which provide multi-year service and support. M&A, particularly bolt-on deals, is a core lever for portfolio enhancement and growth acceleration.
Performance Analysis
Ingersoll Rand closed 2025 with organic order and revenue growth returning to the low single digits, following a challenging first half marked by tough comps and volume softness. ITS posted 3% organic revenue growth in Q4, with all regions contributing positively for the full year, while PST’s life sciences business delivered standout mid-teens organic order growth, offsetting weaker aerospace and defense demand. Adjusted EBITDA margins remained robust at 27.7% for Q4, though year-over-year margin pressure emerged from tariffs and targeted commercial investments.
Free cash flow generation remained strong, supporting $525 million in M&A, $1 billion in share repurchases, and $32 million in dividends for the year. The company’s balance sheet strength, with $3.8 billion in liquidity and leverage well below two times, enables continued capital deployment without sacrificing flexibility. Management highlighted a $1.1 billion recurring revenue backlog, up sharply from prior years, as a key driver of future revenue stability and margin accretion.
- Tariff Impact: Margin headwinds from tariffs were partially offset by pricing actions, with management expecting neutral price-cost in the first half of 2026 and margin expansion in the back half.
- Segment Divergence: PST margins expanded 280 basis points YoY in Q4, driven by life sciences growth and easier comps, while ITS margins declined due to tariffs and commercial reinvestment.
- Order Backlog Visibility: Book-to-bill finished above one for the year, building backlog and providing confidence in near-term execution.
Overall, the quarter reflected resilient execution, with recurring revenue and M&A-driven growth cushioning against sluggish industrial macro trends and setting up for stable 2026 performance.
Executive Commentary
"We're also very pleased with the momentum we continue to see on our recurring revenue initiative, which exceeded $450 million in 2025, with a backlog of recurring revenue of approximately $1.1 billion in future revenue from existing contracts. This is a clear demonstration of how we continue to make great progress towards achieving our recurring revenue target."
Vicente Renal, Chairman and CEO
"We delivered fourth quarter adjusted EBITDA of $580 million, and adjusted EBITDA margins remained strong at 27.7%, reflecting the durability of our operating model, with year-over-year margin pressure primarily driven by tariff impacts and intentional commercial investments for growth."
Vic Kinney, Chief Financial Officer
Strategic Positioning
1. Recurring Revenue Expansion
Recurring revenue now exceeds $450 million annually, with $1.1 billion in contracted backlog, positioning IR for improved revenue predictability and higher-margin service mix. Management is extending the recurring model across more technologies and geographies, aiming for further penetration and stickier customer relationships.
2. Bolt-On M&A as Growth Engine
Sixteen acquisitions in 2025 contributed $275 million in annualized inorganic revenue, with bolt-on deals averaging nine times pre-synergy EBITDA. The pipeline remains robust, with nine LOIs in progress and a focus on life sciences and workflow automation, exemplified by the recent Cynomics acquisition. Larger deals are being cultivated but bolt-ons remain the core strategy.
3. Margin Management Amid Tariffs
Tariff costs were a notable headwind, particularly in ITS, but were largely offset by pricing and productivity actions. Management expects price-cost to be neutral in the first half of 2026, with margin expansion in the back half as tariff impacts annualize and productivity measures gain traction.
4. Life Sciences Outperformance
Life sciences within PST delivered mid-teens organic order growth in Q4, supported by strong pharma, biopharma, and medical device demand, as well as U.S. reshoring trends. Recent product launches and M&A are deepening IR’s presence in this attractive, higher-growth end market.
5. Self-Help and Innovation in China
China returned to positive organic order growth for three consecutive quarters, driven not by market recovery but by localized innovation and technology transfer. IR is leveraging acquired technologies and localizing products to gain share, reflecting a self-help strategy in a challenging market.
Key Considerations
Strategic context for the quarter centers on balancing durable cash flow and growth investments with margin discipline, as IR navigates a muted macro backdrop and ongoing tariff headwinds.
Key Considerations:
- Recurring Revenue Scale-Up: The $1.1 billion backlog and high-margin profile of recurring contracts underpin future stability and margin expansion opportunities.
- M&A Pipeline Health: Bolt-on deals remain plentiful, with disciplined multiples and integration playbook supporting above-market growth, especially in life sciences.
- Tariff and Cost Pressures: Tariff headwinds persist, but proactive pricing and productivity actions are expected to offset margin drag by the second half of 2026.
- Volume Recovery Potential: Guidance embeds flat to slightly negative organic volume in Q1, with potential for upside if short-cycle demand or PMI trends inflect.
- Capital Deployment Discipline: Share repurchases and M&A remain prioritized, but management is not assuming new buybacks or deals in 2026 guidance beyond what is already executed or under LOI.
Risks
Tariff volatility and macro uncertainty remain key risks, with margin pressure persisting until productivity and pricing actions take fuller effect in the second half. End-market demand, particularly for short-cycle industrial products, could disappoint if PMI improvement stalls. Integration risk from continued M&A is present, though mitigated by IR’s disciplined sourcing and playbook. Currency and regional demand variability, especially in China and EMEA, also warrant monitoring.
Forward Outlook
For Q1 2026, Ingersoll Rand guided to:
- Organic revenue roughly flat to slightly down year-over-year.
- EPS growth in the mid-single digits, consistent with full-year trajectory.
For full-year 2026, management maintained guidance:
- Total revenue growth of 2.5% to 4.5%, with 1% organic at the midpoint.
- Adjusted EBITDA of $2.13 to $2.19 billion, with margins flattish year-over-year.
- Adjusted EPS of $3.45 to $3.57, up ~5% at the midpoint.
- Free cash flow conversion of approximately 95%.
Management emphasized that guidance assumes no industrial market recovery, with recurring revenue and backlog providing visibility, and highlighted:
- Potential upside if short-cycle demand or PMI trends improve further.
- Margin expansion expected in the back half as tariff and cost actions take hold.
Takeaways
Ingersoll Rand’s quarter underscores a business model built for resilience, with recurring revenue and disciplined M&A providing ballast against macro softness. Margin management remains a watchpoint as tariffs and investments weigh in the near term, but productivity and pricing actions are expected to restore expansion in the second half.
- Visibility from Recurring Revenue: The $1.1 billion backlog and high-margin service contracts anchor IR’s stable outlook and support long-term value creation.
- Disciplined Growth Playbook: Bolt-on M&A, innovation in China, and life sciences momentum are driving above-market growth and segment diversification.
- Macro Inflection as Key Catalyst: Guidance bakes in no recovery, so any industrial demand pickup could deliver upside, while downside is buffered by backlog and recurring revenue.
Conclusion
Ingersoll Rand’s Q4 2025 results showcase a company balancing durable cash flow, strategic M&A, and recurring revenue expansion to offset macro headwinds and tariff impacts. The 2026 outlook is firmly grounded in current trends, with upside optionality if demand improves and downside protection from backlog and service revenue.
Industry Read-Through
IR’s performance highlights the value of recurring revenue and disciplined bolt-on M&A in industrials, especially as macro recovery remains elusive. Peers with similar service contract penetration or robust acquisition pipelines should see improved stability and margin resilience, while those more exposed to short-cycle volume risk may lag. Tariff headwinds are a sector-wide challenge, but IR’s pricing and productivity response offers a template for margin defense. Life sciences outperformance and China localization strategies are emerging as differentiators for diversified industrials seeking growth beyond core markets.